Search research articles
Contact Us
Filters
Showing results (171-180 of 492) with videos related to
Page
of 50
Sort By:
European Urology
|
January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents
Carmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.
Journal of Proteomics
|
July 22, 2023
Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
The Prostate
|
January 29, 2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer
Donald L Trump, Heather Payne, Kurt Miller, et al.
Journal of Proteomics
|
September 7, 2024
Corrigendum to "Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines" [Journal of Proteomics (2023) Volume 288, Article number 104973]
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 3, 2013
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial
Charles J Ryan, Arturo Molina, Jinhui Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 25, 2014
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
D Lorente, J Mateo, A J Templeton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2013
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
A Bahl, S Oudard, B Tombal, et al.
BJU International
|
June 26, 2003
Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment
G Pentheroudakis, J S De Bono, S B Kaye, et al.
Nature Reviews. Cancer
|
June 18, 2020
Prostate carcinogenesis: inflammatory storms
Johann S de Bono, Christina Guo, Bora Gurel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2019
A decade of clinical development of PARP inhibitors in perspective
J Mateo, C J Lord, V Serra, et al.
Page
of 50
Search research articles
Search
Showing results (171-180 of 492) with videos related to
Sort By:
Page
of 50
European Urology
|
January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents
Carmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.
Journal of Proteomics
|
July 22, 2023
Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
The Prostate
|
January 29, 2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer
Donald L Trump, Heather Payne, Kurt Miller, et al.
Journal of Proteomics
|
September 7, 2024
Corrigendum to "Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines" [Journal of Proteomics (2023) Volume 288, Article number 104973]
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 3, 2013
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial
Charles J Ryan, Arturo Molina, Jinhui Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 25, 2014
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
D Lorente, J Mateo, A J Templeton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2013
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
A Bahl, S Oudard, B Tombal, et al.
BJU International
|
June 26, 2003
Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment
G Pentheroudakis, J S De Bono, S B Kaye, et al.
Nature Reviews. Cancer
|
June 18, 2020
Prostate carcinogenesis: inflammatory storms
Johann S de Bono, Christina Guo, Bora Gurel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2019
A decade of clinical development of PARP inhibitors in perspective
J Mateo, C J Lord, V Serra, et al.
Page
of 50